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Abstract
Background: Lung cancer is a very frequent and lethal tumor with an identifiable risk population. Cytological
analysis and chest X-ray failed to reduce mortality, and CT screenings are still controversially discussed. Recent
studies provided first evidence for the potential usefulness of autoantigens as markers for lung cancer.
Methods: We used extended panels of arrayed antigens and determined autoantibody signatures of sera from
patients with different kinds of lung cancer, different common non-tumor lung pathologies, and controls without
any lung disease by a newly developed computer aided image analysis procedure. The resulting signatures were
classified using linear kernel Support Vector Machines and 10-fold cross-validation.
Results: The novel approach allowed for discriminating lung cancer patients from controls without any lung
disease with a specificity of 97.0%, a sensitivity of 97.9%, and an accuracy of 97.6%. The classification of stage IA/IB
tumors and controls yielded a specificity of 97.6%, a sensitivity of 75.9%, and an accuracy of 92.9%. The
discrimination of lung cancer patients from patients with non-tumor lung pathologies reached an accuracy of
88.5%.
Conclusion: We were able to separate lung cancer patients from subjects without any lung disease with high
accuracy. Furthermore, lung cancer patients could be seprated from patients with other non-tumor lung diseases.
These results provide clear evidence that blood-based tests open new avenues for the early diagnosis of lung
cancer.
Background
Lung cancer is the leading cause of cancer death world-
wide. In 2008, lung cancer is estimated to account for
more than 200,000 new cancer cases and 160,000 cancer
deaths in the United States [1]. Independent of the his-
tological subtype, the five-year survival rate is among
the lowest of all cancers.
Patients with stage IA and IB NSCLC (non small cell
lung cancer) show 5-year survival rates between 60 to
80%, and patients with stage IIA and IIB NSCLC
between 40 to 50% [2]. The 5-year relative survival rate
varies markedly depending on the stage at time of diag-
nosis, from 49 to 16 to 2% for local, regional, and
distant stage disease, respectively [3]. More than two
thirds of lung cancer tumors are diagnosed at late stages
when the survival rate is low [4].
As for other cancers, these data suggest that catching
lung cancer while it is still small and locally defined sig-
nificantly increases the chances of a cure [4]. Recent evi-
dence shows that low dose spiral computed tomography
(CT) detects lung cancer at smaller sizes and earlier
than chest X-ray (CXR) that failed to identify 79% of
lung cancers that were smaller than 2 cm [5]. A major
drawback of low dose CT is the large number of false
positive tests and the diagnosis of indolent tumors
w h i c hi nt u r nl e a d st oa ni n c r e a s e dm o r b i d i t yf r o m
unnecessary surgical treatment [6-8].
Molecular testing offers an opportunity for cancer
detection before the occurrence of histopathological
changes. The immune response to the tumor may
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proteins that have been shed by the tumor and are cir-
culating in the bloodstream. Recently, we identified a
complex humoral immune response that could be used
for the early diagnosis of brain cancer [9]. As of
recently, however, only limited data were available on
the identification and validation of serum markers for
the diagnosis of lung cancer. Single serum markers
showed only a low sensitivity and specificity for the
identification of lung cancer patients [10-15]. Several
studies with smaller panels encompassing few markers
including known autoantigens, cancer associated pro-
teins, and serum proteins like GAGE7, p53, HER2, CEA
or alpha1-antitrypsin provided first evidence that simul-
taneous analysis of several antigens have a higher poten-
tial for separating patients with lung carcinoma from
controls [16-19]. Using a panel of 82 phage peptide
clones we were able to separate squamous cell lung car-
cinoma from control sera with an accuracy of 93%.
Low-grade squamous cell lung carcinoma were distin-
guished from control sera with an accuracy of 92.9%
[20]. Here, we extended our analysis by using an
increased number of newly identified antigens to analyze
not only squamous cell lung carcinoma but also other
NSCLC as well as SCLC (small cell lung cancer).
Furthermore, as a novelty we implemented and
employed an image analysis method for evaluating the
seroreactivity of the arrayed antigens.
Our study was to address the following questions: Can
immunogenic antigens be used to differentiate lung can-
cer patients from controls with a very high sensitivity
and specificity? Can stage I lung carcinomas be sepa-
rated from controls without any lung disease with a
comparable high sensitivity and specificity? Can lung
cancer patients be separated from patients with other
non-tumor lung pathologies (NTLP)? The affirmative
answers to these questions will lay the basis for a pro-
spective study aimed towards early identification of lung
carcinomas.
Methods
Patients’ sera
Blood samples of lung cancer patients were obtained
from the Department of Pneumology of the Saarland
University, from the Department of Cardiothoracic Sur-
gery, SHG Clinic Voelklingen/Saar, and from the
C o l o g n eS m o k i n gS t u d y( C o S m oS), University Hospital
of Cologne. The patient sera stem from 29 NSCLC
patients, and from 18 SCLC patients. The mean age of
NSCLC patients was 64.0 years (ranging from 45 to 83
years), and the mean age of SCLC patients was 60.4
years (ranging from 49 to 74 years). More detailed infor-
mation of lung cancer patients is given in Table 1.
As one control group we combined 80 sera from dif-
ferent volunteers without lung cancer or without other
NTLPs (in the following designated as “controls” or
“control sera”). Out of these 80 controls we obtained 60
sera from healthy blood donors from the Department of
Clinical Haemostaseology and Transfusion Medicine
(Saarland University, Homburg) and 20 sera from
patients with diseases not affecting the lungs (e.g.
slipped disc or myocardial infarction) from the Cologne
Smoking Study (CoSmoS). As a second control group
we used 26 sera of patients with common non-tumor
lung pathologies (NTLP), i.e. 20 patients with COPD/
emphysema, and 6 patients with pneumonia. The NTLP
sera were obtained from the Department of Pneumology
(Saarland University, Homburg), and from the Depart-
ment of Cardiothoracic Surgery, SHG Clinic Voelklin-
gen/Saar. The control sera as well as the NTLP sera
were not matched for age and gender. The mean age of
all control and NTLP patients was 46.5 years, ranging
from 21 to 74 years. The smoking status of the blood
donors was unknown. All blood samples were obtained
with patients’ informed consent. Serum was isolated
from the blood samples and stored as aliquots at -70°C.
Protein macroarray screening
High-density protein arrays consisting of 38,016 E. coli
expressed proteins from the hex1 cDNA expression
library [21] were screened with sera from patients with
various human diseases including tumors and inflamma-
tory diseases. In total, 1827 peptide clones that were
reactive in this primary screening were combined on
customized macroarrays and screened with 47 lung can-
cer sera, 26 NTLP sera, and 80 control sera. Screening
was performed as described previously [22]. In brief,
Table 1 Clinical parameters of the lung cancer patients
NSCLC SCLC
Total number, n (%) 29 (61.7) 18 (38.3)
- adenocarcinoma, n (%) 11 (37.9)
- large cell carcinoma, (%) 9 (31.0)
- squamous cell carcinoma, n (%) 9 (31.0)
age mean, years (range) 64.00 (45-83) 60.44 (49-74)
male, n (%) 16 (55.2) 9 (50)
female, n (%) 13 (44.8) 9 (50)
Clinical staging, n (%)
I 21 (72.4) 1 (5.6)
II 2 (6.9) 0 (0)
III 5 (17.2) 13 (72.2)
IV 0 (0) 2 (11.1)
unknown 1 (3.4) 2 (11.1)
Abbreviations: NSCLC = non-small cell lung cancer, SCLC = small cell lung
cancer
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0.05% Tween 20, 0.5% Triton X-100) and 4 times with
TBS. After incubation in blocking solution (3% nonfat
dry milk powder in TBST (TBS, 0.05% Tween 20)),
macroarrays were incubated over night with sera 1:1000
diluted in blocking solution. After the incubation, sera
were stored for the second incubation round. Three
washing steps with TBST were followed by incubation
with stripping solution at 70°C. Macroarrays were
washed twice with TBST and 4 times with TBS. Incuba-
tion with blocking solution was followed by the second
round of serum incubation over night. Macroarrays
were washed three times with TBST, and incubated
with secondary antibody (rabbit anti-human IgG, IgA,
IgM-Cy5 (H+L)) 1:1000 diluted in blocking solution.
Macroarrays were washed four times with TBST, twice
with TBS and scanned by the GE Healthcare Typhoon
9410 scanner, with 50 μm resolution, and 300 PMT.
Image Analysis of protein macroarrays
We have developed an image analysis pipeline that
ensures a standardized evaluation of the macroarrays. In
a preprocessing step, the scanned images were adjusted,
i.e., slight rotations of the scanned images were cor-
rected and the edges of the image were virtually cut.
Then, the array was segmented into regular subgrids
that were in turn divided into the so-called spot (target)
areas containing exactly one protein spot. By k-means
clustering, the pixels belonging to the spot area of a
protein were divided into foreground and background
pixels. Optionally, the computed spot areas were
adjusted, if the spot pixels exceeded the originally calcu-
lated target area. For the extraction of the dark protein
spots a morphological operator from image processing,
the so-called black top hat, utilizing a square structuring
element has been applied to the image [23]. Finally, the
intensity of each spot was calculated as the mean value
of all pixels of the spot in the processed image. For each
protein array, the automated analysis provided the
intensities of all protein spots. Since each expressed pro-
tein was spotted in duplicates on the macroarray, the
mean intensity of the two replicates was assigned to
each protein. Thus, the image analysis of each macroar-
ray resulted in an autoantibody profile consisting of
1827 integer intensity values ranging from 0 to 255, the
standard range of values in a grey scale image.
Statistical evaluation of autoantibody profiles
To minimize inter-array-effects, the measured autoanti-
body profiles that consist of the intensity values of the
1827 proteins were normalized using quantile
normalization.
For the different classification tasks, we used standard
linear kernel Support Vector Machines (SVMs) [24]
with cost C of 1 that were evaluated by applying 10-fold
cross validation. The classification procedure was
repeated 10 times and the median of sensitivity, specifi-
city, and accuracy was calculated. To test the model for
overfitting, we further validated our prediction approach
by performing so-called permutation tests, i.e., we ran-
domly permuted class labels and performed classifica-
tions with the randomized data.
To directly access the “value” of an antigen with respect
to its ability to separate two serum groups (1 and 2) from
each other, we calculated the area under the Receiver
Operator Characteristics curve (AUC) for each antigen A
as follows: the normalized intensities of all analyzed sera
were used as threshold values. For all thresholds t,w e
considered sera from group 1 with intensity value above t
as true positives (TP), sera from group 1 with intensity
value below t as false negatives (FN), sera from group 2
with intensity value below t as true negatives (TN), and
sera from group 2 with intensity value above t as false
positives (FP). Likewise for all thresholds, specificity (TN/
(TN+FP)) and sensitivity (TP/(TP+FN)) were computed.
Please note that in some cases the classification has to be
inverted. In these cases, sera from group 1 with intensity
value below t are considered as ‘true positives’ (TP). The
Receiver Operator Characteristics (ROC) curve shows
the sensitivity as function of one minus the specificity.
AUC values can range from 0 to 1. An AUC of 0.5 for a
spot means that the distribution of intensity values of
sera from group 1 and sera from group 2 can not be dis-
tinguished. The more the AUC value of an antigen differs
from 0.5, the better this antigen is suited to separate
between the two serum groups. AUCs of 1 or 0 corre-
spond to a perfect separation. Antigens with AUC values
< 0.5 show higher intensity values in sera from group 1
than in sera from group 2. Antigens with AUC values >
0.5 show higher intensity values in sera from group 2
than in sera from group 1 [22].
Results
To identify a larger number of proteins associated with
an autoantibody response we screened high-density pro-
tein macroarrays generated from the fetal brain cDNA
expression library hex1 encompassing more than 38,000
different peptide clones [21]. This primary screening
included sera from patients with various human diseases
including tumors and inflammatory diseases. In total,
we identified 1827 peptide clones that reacted with
serum autoantibodies. We arrayed these peptide clones
and screened the resulting biomarker array with sera
from 29 NSCLC patients, 18 SCLC patients, 26 patients
with common NTLPs, and 80 controls without lung
cancer or other lung pathologies. For each array, we cal-
culated the normalized spot intensities and AUC values
of all antigens as detailed in Material and Methods.
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different classification problems. Besides the separation
of lung cancer versus controls, we built prediction mod-
els for low-grade lung tumors (stage I A/I B) versus
controls, lung cancer stage II, III, IV versus controls,
lung cancer stage IA/IB versus lung cancer stage II, III,
IV, NSCLC versus controls, SCLC versus controls,
NSCLC versus SCLC, lung cancer versus NTLP, lung
cancer versus COPD/emphysema, and lung cancer ver-
sus non-cancer (80 controls and 26 NTLP). To this end,
we applied linear kernel SVMs evaluated by 10 repeti-
tions of 10-fold cross validation.
With our peptide clone set, we were able to differenti-
ate lung cancer sera and control sera with an accuracy
of 97.6%. In detail, we reached a sensitivity of 97.9% and
a specificity of 97.0% (see Figure 1). Given the specificity
of 97.0% and a total of 80 normal sera, we have a False
Positive rate of 3.0%, i.e., only two of the 80 normal
samples have been predicted to be lung cancer samples
by cross-validation. The False Negative rate of 2.1% on
the 47 lung cancer samples means that on average only
one cancer sample has been predicted to be a normal
sample. Taken together, three of all 127 samples have
been wrongly classified while 124 samples have been
correctly predicted.
The small standard deviation (0.007) of the classifica-
tion accuracy demonstrates the stability of classification
results. To test the model for overfitting, we carried out
100 permutation tests in a stratified manner that yielded
a median accuracy of 54.3%. This can be explained by
the differences in the class sizes. Permutation tests with
even label distributions lead to an average accuracy of
approximately 50%. Additionally, we carried out classifi-
cation in stage I A/I B lung cancer sera and control
sera. This comparison reached a sensitivity of 75.9%, a
specificity of 97.6%, and an accuracy of 92.9%.
Next, we asked whether our peptide clone set also
permits to discriminate between the two different histo-
logical lung cancer subgroups NSCLC and SCLC. While
we were not able to distinguish between NSCLC and
SCLC with very high accuracy (67.3%), we succeeded in
separating NSCLC sera from control sera with a sensi-
tivity of 97.8%, a specificity of 85.7%, and an accuracy of
94.6%. The classification of SCLC versus controls
reached a sensitivity of 99.3%, a specificity of 79.4%, and
an accuracy of 95.7%. As further controls, we used sera
from patients with other non-tumor lung pathologies, e.
g. COPD/emphysema and pneumonia. We were able to
distinguish lung cancer patients from patients with
NTLPs with an accuracy of 88.5%. We combined all
non-cancer sera (80 sera of blood donors without any
lung disease and the 26 sera of patients with NTLPs)
and calculated the classification lung cancer versus non-
cancer. Here, we reached an accuracy of 92.2%, a sensi-
tivity of 96.7%, and a specificity of 88.2%. The classifica-
tion lung cancer versus COPD/emphysema reached an
accuracy of 78.8%, a sensitivity of 92.6%, and a specifi-
city of 40.9%. For all ten classification tasks, permutation
tests showed a significantly decreased performance (Wil-
coxon Mann-Withney p-value < 10
-10). All classification
results and the 95% Confidence Intervals (CI) are sum-
marized in Table 2. The AUC values for all ten classifi-
cation tasks and each antigen are given in Additional
file 1.
Discussion
There is widespread consensus that detection of cancer
at an early stage can be live saving. Lung cancer screen-
ing however remains a controversial issue since CXR
and sputum cytology screening showed no benefit
towards reduced mortality [6,8]. Low dose CT can
detect tumors that are smaller in size and are at an ear-
lier stage in development. However, the high sensitivity
of low dose CT screening is balanced by a rather high
rate of false positive scans of up to 20% [25], which ulti-
mately prove benign after unnecessary surgical interven-
tions [26]. In summary, screening of persons
asymptomatic for lung cancer is not recommended at
present neither by CXR, sputum cytology nor by low
dose CT [27].
Nevertheless, the identification of small lung cancers
had lead to renewed interest in more specific markers
that may contribute to an early identification of lung
cancer. While the immune system is not efficient in
Figure 1 Estimated probabilities for each serum to be a control
sample. Here, each ‘C’ corresponds to serum of patients without
any lung disease and each ‘L’ to a lung cancer serum. The
horizontal black line defines the classification threshold.
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can be utilized as diagnostic tool: Autoantibodies against
cancer-associated antigens can be measured up to 5
years before symptomatic disease [16], have a long half-
life [28], and can be detected at low costs. Single auto-
antigens that are immunogenic in lung cancer show a
low sensitivity and specificity [10-15]. Combined mea-
sures of antibody reactivities to a panel of several
arrayed proteins have been used to discriminate sera of
lung cancer patients from control sera. These proteins
include known tumor associated antigens like p53 and
c-myc, known serum proteins like carcinoembryonic
antigen and apha1-antitrypsin, and five predictive
phage-expressed proteins recognized by serum antibo-
dies [16-19]. There was no overlap between the protein
sets used in these studies indicating a large number of
immunogenic proteins that still await identification.
Lung carcinoma show complex cellular abnormalities
including multiple genetic changes, like DNA sequence
alterations, copy number changes, and aberrant methyla-
tion [29-32]. Extended antigen panels may most ade-
quately analyze this cellular heterogeneity. The
examination of a large antigen panel that reflects the
complexity of immunogenic alterations in tumor cells
likely contributes to a reliable classification with high
accuracy, sensitivity, and specificity. The disadvantage of
screening complex cDNA expression libraries with a
large number of sera is, however, an inevitable degree of
variability due to expression variability of bacterial in
vivo expression systems. Nevertheless, in this study we
were able to differentiate lung cancer patients from con-
trols with high accuracy. Likewise, we were able to sepa-
rate lung cancer patients from patients with non-tumor
diseases of the lung with high accuracy.
Future studies have to elucidate whether the analysis
of subgroups of lung cancer will be possible by smaller
antigen panels. Smaller panels will facilitate to use full-
length purified proteins for diagnostic purposes at
affordable costs. Ideally, such antigen sets will even ren-
der the separation of histopathological subgroups like
SCLC and NSCLC feasible.
The usefulness of complex antigen patterns for early
lung cancer diagnosis awaits further confirmation by
prospective studies. The reduction of the lung cancer
associated mortality is an independent problem. There
is an evident correlation between tumor size and survi-
val time [4] for lung cancer. However, some lung can-
cers metastasize while the original tumor is still small. It
is supposed that metastasis appears to primarily depend
on the tumor genetics and the angiogenesis. In sum-
mary, our study shows that the immune system, even
though not effective in destroying the tumor, may very
well provide highly sensitive and specific markers for
lung cancer in its early development.
Conclusions
Autoantibodies are potentially well suited as cancer bio-
markers, because only a minimal-invasive intervention is
needed for their extraction, they can be easily measured,
they are stable in blood, and they have a long half-life.
Table 2 Summary of the results of the ten different classification tasks.
Classification task Accuracy % Sensitivity % Specificity %
lung cancer vs controls 97.6
(CI: 97.3-97.9)
97.9
(CI: 96.6-97.8)
97.0
(CI:97.6-98.3)
lung cancer stage IA/IB vs controls 92.9
(CI: 92.4-93.4)
75.9
(CI: 73.7-78.2)
97.6
(CI: 97.3-97.8)
lung cancer stage II, III, IV vs controls 97.6
(CI: 97.1-98.0)
99.9
(CI: 87.2-91.0)
89.1
(CI: 99.7-100.0)
lung cancer stage IA/IB vs lung cancer stage II, III, IV 66.5
(CI: 63.8-69.1)
65.7
CI: 62.2-69.2)
67.3
(CI: 64.6-70.0)
NSCLC vs controls 94.6
(CI: 93.9-95.2)
97.8
(CI: 97.5-98.2)
85.7
(CI: 83.8-87.5)
SCLC vs controls 95.7
(CI: 95.2-96.0)
99.3
(CI: 99.0-99.6)
79.4
(CI: 77.5-81.4)
NSCLC vs SCLC 67.3
(CI: 65.4-69.3)
76.7
(CI: 74.4-79.0)
52.2
(CI: 50.0-54.4)
lung cancer vs NTLP 88.5
(CI: 88.0-89.3)
99.8
(CI: 99.5-100.0)
42.4
(CI: 40.2-44.6)
lung cancer vs non-cancer 92.2
(CI: 91.6-92.9)
96.7
(CI: 95.5-97.9)
88.2
(CI: 87.5-88.8)
lung cancer vs COPD/emphysema 78.8
(CI: 78.0-79.7)
92.6
(CI: 91.6-93.5)
40.9
(CI: 38.8-43.0)
Abbreviations: NSCLC = non-small cell lung cancer, SCLC = small cell lung cancer, NTLP = non-tumor lung pathology, controls = patients without any lung
disease, non-cancer = controls and NTLP, CI = 95% Confidence Intervals
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nostic sensitivity. Here, we show that the combination
of an expanded number of autoantigens for the creation
of complex autoantibody profiles allow for the differen-
tiation of lung cancer patients from patients with other
common non-tumor lung diseases or healthy blood
donors with high accuracy.
List of abbreviations used
NTLP: non-tumor lung pathology; NSCLC: non-small
cell lung cancer; SCLC: small cell lung cancer; SVM:
Support Vector Machine; AUC: area under the receiver
operator characteristics curve; CI: Confidence Interval;
TP: true positives; TN: true negatives; FP: false positives;
FN: false negatives; CXR: chest X-ray; CT: computed
tomography; COPD: chronic obstructive pulmonary
disease.
Additional file 1: Summary of the AUC values for all ten
classification tasks and each analyzed antigen. Antigens considered
as informative (AUC value < 0.3 or > 0.7) were written in red.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1465-9921-11-
18-S1.XLS]
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